The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for ...
LATE is a prevalent condition in late life and can contribute to memory loss and cognitive decline, according to report ...
Verywell Health on MSN5d
What's New in Alzheimer's Treatment?We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
StudyFinds on MSN2d
Delayed dream sleep could be early warning sign of Alzheimer’sDiscover the link between REM sleep and Alzheimer's disease. Learn how delayed REM sleep may indicate elevated protein levels ...
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
Verywell Health on MSN2d
Why It's Hard for Patients to Get the Newest Alzheimer's DrugsAccess to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...
NeurEYE uses AI and anonymized eye scans to assess dementia risk and brain health indicators, leveraging data from Scottish ...
PEOPLE often think of Alzheimer’s when they think of dementia. It’s the most common type of dementia, accounting for 60-80 ...
Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...
Because it can only be diagnosed with an autopsy, the neurodegenerative disease is difficult to pin in cases of professional ...
First patients with memory problems join ‘revolutionary’ trial by Oxford and Cambridge universities which could lead to ‘Holy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback